[1]徐　舒　岳志健　周晓平　王建军　王来兴　张煜辉　刘建民.人脑胶质瘤EPO与CD105表达及意义[J].中国临床神经外科杂志,2018,(05):311-314.[doi:10.13798/j.issn.1009-153X.2018.05.003]
　XU Shu,YUE Zhi-jian,ZHOU Xiao-ping,et al.Expressions of erythropoietin and CD105 in glioma tissues in patients with gliomas and their meanings[J].,2018,(05):311-314.[doi:10.13798/j.issn.1009-153X.2018.05.003]
点击复制

人脑胶质瘤EPO与CD105表达及意义()
分享到：

《中国临床神经外科杂志》[ISSN:1009-153X/CN:42-1603/TN]

卷:
期数:
2018年05期
页码:
311-314
栏目:
论著
出版日期:
2018-05-25

文章信息/Info

Title:
Expressions of erythropoietin and CD105 in glioma tissues in patients with gliomas and their meanings
文章编号:
1009-153X（2018）05-0311-04
作者:
徐　舒　岳志健　周晓平　王建军　王来兴　张煜辉　刘建民
作者单位：213000 江苏常州，南京中医药大学附属常州中医院神经外科（徐　舒）；200433 上海，第二军医大学长海医院神经外科（岳志健、周晓平、王来兴、张煜辉、刘建民），病理科（王建军）
Author(s):
XU Shu1;  YUE Zhi-jian2;  ZHOU Xiao-ping2;  WANG Jian-jun3;  WANG Lai-xing2;  ZHANG Yu-hui2;  LIU Jian-min2.
1. Department of Neurosurgery, Affiliated Changzhou Chinese Traditional Medicine Hospital, Nanjing University of Chinese Traditional Medicine, Changzhou, 21300, China; 2. Department of Neurosurgery, Changhai Hospital, The Second Military Medical University, Shanghai 200433, China; 3. Department of Pathology, Changhai Hospital, The Second Military Medical University, Shanghai 200433, China
关键词:
胶质瘤; 促红细胞生成素; CD105
Keywords:
Gliomas;  Erythropoietin;  CD105;  Expression;  Malignant degree;  Survival time;  Relationship
分类号:
R 739.41; Q 786
DOI:
10.13798/j.issn.1009-153X.2018.05.003
文献标志码:
A
摘要:
目的 探讨人脑胶质瘤组织促红细胞生成素（EPO）和CD105的表达变化及其意义。方法 收集2002~2008年人脑胶质瘤标本152例，其中WHO分级Ⅰ级4例，Ⅱ级32例，Ⅲ级68 例，Ⅳ级48例；取同期颅脑损伤内减压术切除正常脑组织20例为对照，采用免疫组化染色分析EPO及CD105表达。收集2005~2008年人脑胶质瘤标本胶质瘤17例（WHO Ⅱ级6例，Ⅲ~Ⅳ级11例），正常对照5例，采用实时荧光定量PCR检测EPO mRNA表达变化。术后随访截止2010年4月23日，应用Kaplan-Meier生存曲线分析高级别（Ⅲ~Ⅳ级）胶质瘤生存曲线。结果 胶质瘤EPO表达阳性率（60.5%，92/152）明显高于正常脑组织（10%，2/20；P<0.001），胶质瘤EPO表达强度与病理分级呈正相关（rs=0.368，P<0.001）。EPO表达阳性组CD105阳性率明显高于阴性组（P<0.05），EPO高表达组明显高于低表达组（P<0.05）。Ⅱ级胶质瘤组EPO mRNA表达水平明显高于正常组与Ⅲ~Ⅳ级胶质瘤组（P<0.05）。对于高级别（WHO Ⅲ~Ⅳ级）胶质瘤，EPO低表达组中位生存时间为12个月，高表达组为36个月；EPO低表达组累积生存率明显低于高表达组（P<0.05）。结论 人脑胶质瘤EPO蛋白的表达与病理级别及新生血管正相关；WHO Ⅱ级胶质瘤EPO mRNA在转录水平已上调；WHO Ⅲ~Ⅳ级组胶质瘤EPO表达高者生存期长。
Abstract:
Objective To explore the expressions of erythropoietin (EPO) and CD105 in human glioma tissues and their meanings. Methods The expressions of EPO and CD105 in 152 cases of gliomas tissues including 7 cases of WHO grade Ⅰ, 29 cases of WHO grade Ⅱ, 68 cases of WHO grade Ⅲ and 48 cases of WHO grade Ⅳ and 20 cases of normal brain tissue were determined by immunohistochemiscal technique. The expression of EPO mRNA in 17 cases of gliomas including 6 cases of WHO gradeⅡ and 11 cases of WHO gradeⅢ~Ⅳ and 5 cases of normal brain tissue were detected by real time PCR. The relationship of EPO expression with survival rate was analyzed by survival curve. Results The level of EPO expression in the glioma tissues were significantly higher than that in the normal brain tissues (P<0.01), and was positively correlated with the WHO grade of the tumor (rs=0.368, P<0.01). The CD105 expression level was significantly higher in the positive EPO expression group than that in the negative EPO expression group (P<0.05). The level of EPO mRNA expression was significantly higher in the WHO grade Ⅱ glioma tissues than those of normal brain tissues (P<0.01) and WHO grade Ⅲ~Ⅳ gliomas tissues (P<0.05). The survival curve analysis showed that the survival time was significantly longer in the patients with high WHO grade gliomas in which EPO was strongly expressed than that in the patients with high WHO grade gliomas in which EPO was weakly expressed (P<0.05). Conclusions Our results suggest that the level of EPO expression in the tumorous tissue is positively related to WHO grade and neovascularization of glioma. The level of EPO mRNA expression in WHO grade Ⅱ glioma has been upregulated in DNA transcription. The patients with WHO Ⅲ~Ⅳ gliomas in whom EPO protein is strongly expressed survive longer compared to the patients with WHO Ⅲ~Ⅳ gliomas in whom EPO is weakly expressed.

参考文献/References:

[1] Zhou B, Damrauer JS, Bailey ST, et al. Erythropoietin pro- motes breast tumorigenesis through tumor-initiating cell self-renewal [J]. J Clin Invest, 2014, 124(2): 553-563.
[2] Grover A, Mancini E, Moore S, et al. Erythropoietin guides multipotent hematopoietic progenitor cells toward an ery- throid fate [J]. J Exp Med, 2014, 211(2): 181-188.
[3] Sugawa M, Sakurai Y, Ishikawa-Ieda Y, et al. Effects of erythropoietin on glial cell development; oligodendrocyte maturation and astrocyte proliferation [J]. Neurosci Res, 2002, 44(4): 391-403.
[4] Robertson CS, Hannay HJ, Yamal JM, et al. Effect of ery- thropoietin and transfusion threshold on neurological reco- very after traumatic brain injury: a randomized clinical trial [J]. JAMA, 2014, 312(1): 36-47.
[5] Jaspers A, Baron F, Willems E, et al. Erythropoietin therapy after allogeneic hematopoietic cell transplantation: a pros- pective, randomized trial [J]. Blood, 2014, 124(1): 33-41.
[6] Kim WS, Zhu Y, Deng Q, et al. Erythropoiesis from human embryonic stem cells through erythropoietin-independent AKT signaling [J]. Stem Cells, 2014, 32(6): 1503-1514.
[7] Barbosa C, Romao L. Translation of the human erythro- poietin transcript is regulated by an upstream open reading frame in response to hypoxia [J]. RNA, 2014, 20(5): 594- 608.
[8] Yang Z, Wang H, Jiang Y, et al. VEGFA activates erythro- poietin receptor and enhances VEGFR2-mediated patholo- gical angiogenesis [J]. Am J Pathol, 2014, 184(4): 1230- 1239.
[9] Ruiz M, Martinez-Vidal AF, Morales JM, et al. Neurode- generative changes are prevented by erythropoietin in the pmn model of motoneuron degeneration [J]. Neuropharma- cology, 2014, 83: 137-153.
[10] 刘　坤，姚　阳，杨　宇，等. 促红细胞生成素预处理对脑 缺血再灌注大鼠水通道蛋白4的影响[J]. 中风与神经疾 病杂志，2014，31（2）： 111-113.
[11] 高广生，张福森. 促红细胞生成素对心肺复苏后大鼠神经 功能及脑细胞凋亡的影响[J]. 中华行为医学与脑科学杂 志，2014，23（5）： 402-404.
[12] Mohyeldin A, Dalgard CL, Lu H, et al. Survival and invasi- veness of astrocytomas promoted by erythropoietin [J]. J Neurosurg, 2007, 106(2): 338-350.
[13] Livak KJ, Schmittgen TD. Analysis of relative gene expre- ssion data using real-time quantitative PCR and the 2 (-Delta Delta C(T)) method [J]. Methods, 2001, 25(4): 402- 408.
[14] Kaur B, Khwaja FW, Severson EA, et al. Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis [J]. Neuro Oncol, 2005, 7(2): 134-153.
[15] 刘志忠，张宇新，阚志生，等. 脑胶质瘤促红细胞生成素的 表达及其生物学意义[J]. 实用肿瘤杂志，2005，20（1）： 43-45.
[16] 徐　舒，岳志健，周晓平，等. 人脑胶质瘤组织促红细胞生 成素受体的表达及其与新生血管的关系[J]. 中华实验外 科杂志，2013，30（5）：977-979.
[17] Stuben G, Thews O, Pottgen C, et al. Recombinant human erythropoietin increases the radiosensitivity of xenografted human tumours in anaemic nude mice [J]. J Cancer Res Clin Oncol, 2001, 127(6): 346-350.

相似文献/References:

[1]常英男　王　策　赵天书.SOX2基因在胶质瘤中的表达及生物学作用[J].中国临床神经外科杂志,2016,(05):270.[doi:10.13798/j.issn.1009-153X.2016.05.005]
　CHANG Ying-nan,WANG Ce,ZHAO Tian-shu..Expression of SOX2 gene and its biological role in human gliomas[J].,2016,(05):270.[doi:10.13798/j.issn.1009-153X.2016.05.005]
[2]赛　克　陈忠平.胶质瘤的疗效评价[J].中国临床神经外科杂志,2016,(06):321.[doi:10.13798/j.issn.1009-153X.2016.06.001]
[3]许　耿　路俊锋　杨　忠　施建斌　吴秋月　王　烨　庄冬晓　吴劲松.神经电生理监测技术在功能区胶质瘤术中的应用[J].中国临床神经外科杂志,2016,(06):323.[doi:10.13798/j.issn.1009-153X.2016.06.002]
　XU Geng,LU Jun-feng,YANG Zhong,et al.Application of intraoperative neuroelectrophysiologic monitoring to gliomas resection in eloquent function brain regions[J].,2016,(05):323.[doi:10.13798/j.issn.1009-153X.2016.06.002]
[4]李剑峰　陈银生　赛　克　张湘衡　柯　超　杨群英　牟永告　许海雄　陈忠平.173例胶质瘤预后的影响因素分析[J].中国临床神经外科杂志,2016,(06):327.[doi:10.13798/j.issn.1009-153X.2016.06.003]
　LI Jian-feng,CHEN Yin-sheng,SAI Ke,et al.Prognostic factors for gliomas: analysis of 173 cases[J].,2016,(05):327.[doi:10.13798/j.issn.1009-153X.2016.06.003]
[5]云德波　杨宇焦　张　逵　范润金　张　渊　杜贻庆.瘤周谷氨酸、天门冬氨酸水平与胶质瘤继发性 癫痫的相关性[J].中国临床神经外科杂志,2016,(06):331.[doi:10.13798/j.issn.1009-153X.2016.06.004]
　YUN De-bo,YANG Yu-Jiao,ZHANG Kui,et al.Relationship of levels of glutamate and aspartate in peritumorous tissues with seizures in patients with gliomas[J].,2016,(05):331.[doi:10.13798/j.issn.1009-153X.2016.06.004]
[6]黄书岚　成于思　王　辉　汪超甲.FAK siRNA重组质粒的构建及其对胶质瘤U251细胞 增殖及侵袭能力的抑制作用[J].中国临床神经外科杂志,2016,(06):336.[doi:10.13798/j.issn.1009-153X.2016.06.006]
　HUANG Shu-lan,CHENG Yu-si,WANG Hui,et al.Construction of siRNA recombinant plasmid targeting focal adhesion kinase gene and its effect on the proliferation and invasiveness of human glioma U251cells[J].,2016,(05):336.[doi:10.13798/j.issn.1009-153X.2016.06.006]
[7]林　雨　张　恺　李　帅　杨学军.磁共振数字化手术单元在指导胶质瘤治疗中的作用[J].中国临床神经外科杂志,2016,(06):345.[doi:10.13798/j.issn.1009-153X.2016.06.009]
[8]戴黎明　徐成仕　王泽芬　曹长军　李志强.VEGF单抗对低氧环境下C6胶质瘤细胞侵袭性的影响[J].中国临床神经外科杂志,2016,(04):219.[doi:10.13798/j.issn.1009-153X.2016.04.009]
　DAI Li-ming,XU Cheng-shi,WANG Ze-fen,et al.Effect of nonoclonal antibody of VEGF on C6 glioma cells invasiveness under hypoxia and the role of FAK/Pyk2[J].,2016,(05):219.[doi:10.13798/j.issn.1009-153X.2016.04.009]
[9]彭泽生　田道锋　张申起　陈谦学.miR-370-3p对胶质母细胞瘤U87-MG细胞株增殖能力的影响[J].中国临床神经外科杂志,2016,(04):223.[doi:10.13798/j.issn.1009-153X.2016.04.010]
　PENG Ze-sheng,TIAN Dao-feng,ZHANG Shen-qi,et al.Effects of MircoRNA-370-3p on proliferation of glioma cell line U87-MG and its potential mechanism[J].,2016,(05):223.[doi:10.13798/j.issn.1009-153X.2016.04.010]
[10]冯　驰　郭双毅　程龙海　罗　杰.氯喹通过抑制自噬促进TRAIL诱导的胶质瘤细胞凋亡[J].中国临床神经外科杂志,2016,(04):227.[doi:10.13798/j.issn.1009-153X.2016.04.011]
　FENG Chi,GUO Shuang-yi,CHENG Long-hai,et al.Chloroquine promotes TRAIL-induced apoptosis of glioma cells through inhibition of autophagy[J].,2016,(05):227.[doi:10.13798/j.issn.1009-153X.2016.04.011]

备注/Memo

备注/Memo:
基金项目：上海市重点科技攻关计划（08411953600） 通讯作者：岳志健，E-mail：yuezj638@163.com
更新日期/Last Update: 2018-04-25